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Abstract 
Background 
Postmenopausal hormone therapy use has been associated with lower colorectal cancer risk 
in observational studies. However, the role of endogenous sex hormones in colorectal 
cancer development in post-menopausal women is uncertain. 
Methods 
The relation of colorectal cancer risk with circulating levels of estradiol, estrone, free 
(bioactive) estradiol, progesterone and sex hormone-binding globulin (SHBG) was 
determined in a nested case-control study of 1,203 postmenopausal women (401 cases and 
802 age and race/ethnicity-matched controls) enrolled in the Women’s Health Initiative 
Clinical Trial (WHI-CT) who were not assigned to the estrogen-alone or combined estrogen 
plus progestin intervention groups.  We used multivariable-adjusted conditional logistic 
regression models that included established colorectal cancer risk factors.  All statistical 
tests were two-sided. 
Results  
Comparing extreme quartiles, estrone (odds ratio [OR]q4-q1=0.44, 95% confidence interval 
[95%CI]: 0.28-0.68; P-trend=0.001), free estradiol (ORq4-q1=0.43, 95%CI: 0.27-0.69; P-
trend=<0.0001) and total estradiol (ORq4-q1=0.58, 95%CI: 0.38-0.90; P-trend=0.08) were 
inversely associated with colorectal cancer risk. SHBG levels were positively associated with 
colorectal cancer development (OR[q4-q1]=2.30, 95%CI: 1.51-3.51; P-trend=<0.0001); this 
association strengthened after further adjustment for estradiol and estrone (ORq4-q1=2.50, 
95%CI: 1.59-3.92; P-trend<0.0001). Progesterone was not associated with colorectal cancer 
risk. 
Conclusion   
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Endogenous estrogen levels were inversely, and SHBG levels positively, associated with 
colorectal cancer risk, even after control for several colorectal cancer risk factors. These 
results suggest that endogenous estrogens may confer protection against colorectal 
tumorigenesis among post-menopausal women. 
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Introduction  
Colorectal cancer is the third most common cancer worldwide with more than one million 
new cases diagnosed every year (1). Colorectal cancer incidence rates are lower among 
women compared to men across all age categories and it has been hypothesized that higher 
exposure to estrogens among women may confer a protective role (2). Consistent with this 
hypothesis are findings from a substantial body of epidemiologic literature that report a 20-
40% lower incidence of colorectal cancer among users, than non-users, of early high-dose 
oral contraceptives (3) and of post-menopausal hormone therapy (HT) (4-9). However, in 
contrast to the results from observational studies of HT use and colorectal cancer, the 
Women’s Health Initiative Clinical Trial (WHI-CT) reported no effect of estrogen-alone 
therapy on colorectal cancer risk (10). Further, while administration of estrogen plus 
progestin was initially found to yield a 44% reduction in risk of developing colorectal cancer 
compared to the placebo group (10), longer follow-up revealed this finding was a probable 
consequence of diagnostic delay (8).  
 
Data from studies that have evaluated the association of endogenous, circulating estrogens 
on colorectal cancer incidence are limited and contradictory. We previously reported an 
unexpected borderline-statistically significant positive association between endogenous 
estradiol levels and colorectal cancer incidence among participants of the WHI observational 
study (WHI-OS), that was independent of related factors such as body habitus and 
hyperinsulinemia (11); although that study did not measure circulating levels of other sex 
hormones, such as estrone, progesterone, and free estradiol, or sex hormone binding 
globulin (SHBG). Since the publication of the WHI-OS analysis, two follow-up studies 
conducted in the New York University Women’s Health Study (NYUWHS) (12) and a joint 
Nurses’ Health Study (NHS) and Women’s Health Study (WHS) analysis reported no 
association between estradiol levels and colorectal cancer risk (13). Data on other 
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components of the sex hormone axis, including estrone and sex hormone binding globulin 
(SHBG), and their association with colorectal cancer are also sparse, and no studies have 
evaluated the association of endogenous progesterone levels with colorectal cancer.    
 
Therefore, to further knowledge on the role of endogenous estradiol and other sex hormones 
on colorectal cancer development, we conducted a prospective evaluation of estradiol, 
estrone, free (unbound) estradiol, progesterone, and SHBG and colorectal cancer risk using 
the current gold standard sex hormone assays (14;15) among participants of the WHI-CT 
who were not assigned to the estrogen-alone or combined estrogen plus progestin 
intervention arms, and were therefore not using exogenous hormones at baseline. We also 
controlled for other serologic factors that are related to sex hormone levels and adiposity, 
and have been linked to colorectal cancer incidence in some studies, namely fasting insulin, 
free insulin-like growth factor (IGF)-I, and C-reactive protein (CRP).  
 
Methods 
Study Population and Collection of Blood Samples 
At study baseline (1993-1998), 68,133 postmenopausal women (aged 50-79 years) were 
enrolled into the WHI-CT, which had four components: (1) hormone therapy with estrogen-
alone (E); (2) hormone therapy with combined estrogen plus progestin (E+P); (3) dietary 
modification (DM); and (4) calcium plus vitamin D (CaD)  (16). Women were recruited from 
40 clinical centers across the United States (US) using mass-mailing to age-eligible women 
who were enumerated from voter registration, driver’s licenses, and HCFA records (17). 
Fasting blood samples were collected from all participants at baseline and during the Year 1 
clinic visits. Blood samples were labeled, centrifuged and stored at -70°C within 2 hours of 
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collection. All specimens were shipped to the central WHI biorepository for long-term 
storage. 
Data collection 
All women enrolled in the WHI-CT completed a baseline clinic visit and detailed 
questionnaire that included information regarding medical and reproductive history, family 
medical history, a food frequency questionnaire, an inventory of currently used medications 
(including dietary supplements), and an assessment of psychosocial factors, quality-of-life, 
and health-related behaviors. During the baseline visit at the WHI Clinical Centre, height, 
weight, waist/hip circumferences and blood pressure measurements were taken. 
Questionnaires were repeated annually thereafter. Incident cancers indicated in these 
questionnaires or by other self-report were subsequently confirmed through centralized 
review of all pathology reports, discharge and consultant summaries, operative and 
radiology reports, and tumor registry abstracts. 
 
Selection of Case and Control Participants 
Eligibility criteria for case and control participants were: (i) inclusion within the WHI-CT, but 
not assigned to the E or E+P intervention arms; (ii) no baseline use of hormones (pill, skin 
patch, cream, or shot), unless women underwent a washout period which ended prior to 
baseline blood draw; (iii) no history of colorectal cancer at baseline; (iv) availability of 
adequate serum sample (1.2 ml); (v) colorectal cancer diagnosed at least 1 year after 
randomization (cases only); (vi) no history of diabetes at baseline; (vii) no use of diabetes 
medication at baseline. Using these criteria, as of August 15, 2008, 401 colorectal cancer 
cases were eligible for this analysis. Incident colorectal cancer was defined as the diagnosis 
of disease (International Classification of Diseases for Oncology site codes 153.3-153.4, 
153.6-153.9, and 154.0-154.1) after >1 year of follow-up. Each case was matched with 2 
controls (n=802 controls) that exactly met the matching criteria of: age (±0 years), ethnicity 
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(White, Black, Hispanic, American Indian, Asian/Pacific Islander, or unknown), HT 
assignments (E placebo, P placebo, or not randomized (NR), DM assignments (intervention, 
control or NR), and CaD assignments (intervention, control or NR). Control selection was 
performed in a time-forward manner, selecting one control for each case first from the risk 
set at the time of the case’s event and this process was then repeated for the selection of 
the second control. 
 
Laboratory Methods 
All serologic assays were performed in the laboratory of Dr Frank Stanczyk, University of 
Southern California, Los Angeles, CA. Serum levels of estradiol, estrone and progesterone 
were quantified by validated, previously described radioimmunoassay (RIAs) (14;15). Prior 
to the RIA, the steroid hormones were extracted from serum with hexane:ethyl acetate (3:2 
ratio). Estradiol, estrone, and progesterone were then separated from each other and from 
interfering steroids by Celite column partition chromatography using ethylene glycol as the 
stationary phase. Progesterone was eluted with trimethylpentane, and estrone and estradiol 
were eluted with 15% and 40% ethyl acetate in trimethylpentane, respectively. The 
sensitivities of the estradiol, estrone and progesterone assays were 2 pg/mL, 4 pg/mL, and 
10 pg/mL, respectively; all measured values were above the assay sensitivity lower limit. 
Assay specificity was achieved by undertaking organic-solvent extraction and 
chromatographic steps prior to quantification of the analytes, and/or use of highly specific 
anti-sera. Assay accuracy was established by demonstrating consistency between 
measured concentrations of a serially diluted analyte in serum and the corresponding 
standard curve. SHBG was quantified by a solid-phase, two-site chemiluminescent 
immunoassay using the Immulite Analyzer (Siemens Medical Solutions Diagnostics, Los 
Angeles, CA). The solid phase is a polystyrene bead with a monoclonal antibody specific for 
SHBG. Free estradiol levels were calculated using total estradiol concentrations, SHBG 
concentrations and an assumed constant for albumin in a validated algorithm (18;19). This 
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method does not distinguish between free estradiol and bioavailable (non-SHBG bound) 
estradiol. Insulin and free IGF-I concentrations were determined by enzyme-linked 
immunosorbent assays (ELISAs) using commercially available immunoassay kits from 
Diagnostic Systems Laboratories (DSL; Webster, Texas). CRP levels were determined using 
a solid-phase chemiluminescent immunometric assay on the Immulite analyzer (Siemens 
Medical Solutions Diagnostics, Los Angeles, CA). Cases and matched controls were 
assayed together in batches of 41 or less depending on where the blind duplicates fell in the 
random distribution within the pull - 10 blind duplicates (5 pairs) were analyzed for every 100 
participant samples. The mean intra-assay coefficients of variation from the duplicate 
samples were 11% for estradiol, 10% for estrone, 13% for progesterone, 4% for SHBG, 8% 
for insulin, 16% for free IGF-I, and 4% for CRP. 
 
Statistical Analysis 
Univariate differences between cases and controls were assessed using the Wilcoxon two-
sample tests for continuous variables and χ2 tests for categorical variables. Multivariable 
conditional logistic regression, stratified by case-control set, was used to compute odds 
ratios (OR) and 95% confidence intervals (95%CI) for the associations between circulating 
levels of sex hormones and colorectal, colon, and rectal cancers. Participants were divided 
into quartiles (colorectal and colon cancers) or tertiles (rectal cancer) based on the 
distributions of circulating levels of sex hormones in the control group. Statistical tests for 
trend for a given analyte were calculated using the ordinal quartile entered into the models 
as a continuous variable. The multivariable models were adjusted for a set of a priori-
determined colorectal cancer risk factors, namely waist circumference, alcohol consumption, 
family history of colorectal cancer, physical activity, smoking status, and non-steroidal anti-
inflammatory drug (NSAID) use. Additional adjustment for dietary intakes of fiber, calcium, 
and folate resulted in virtually unchanged OR estimates. Further adjustment for circulating 
levels of insulin and free IGF-I were also made for the sex hormone, SHBG, and waist 
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circumference models. The estrone and total estradiol models were additionally adjusted for 
SHBG, and vice-versa. Possible non-linear effects were modeled using restricted cubic 
spline models with five knots placed at the 10th, 25th, 50th, 75th, and 95th percentiles for 
estradiol, estrone, free estradiol, and SHBG models. Stratified analyses according to body 
mass index (BMI; <30 or ≥30 kg/m2), waist circumference (above and below median based 
on distribution of the control group) and previous use of HT were also performed. 
Heterogeneity of associations for colon and rectal cancer sub-sites was assessed by 
calculating X2 statistics using one degree of freedom from meta-analysing the ORs and 
95%CI in the highest sex hormone and SHBG quantiles. 
 
In sensitivity analyses, to ensure that exogenous hormone use was not biasing our results, 
individuals with total estradiol levels >30 pg/mL and current HT users (who underwent a 
washout period prior to study onset) were excluded and all models were re-run. Also in 
sensitivity analyses, the case-control match was broken and the associations were re-
analyzed using unconditional logistic regression, plus additional adjustment for age and 
race/ethnicity. All analyses were also performed when cases diagnosed within the first three 
years of follow-up were excluded. Statistical tests used in the analysis were all two-sided 
and a P-value of <0.05 was considered statistically significant. Analyses were conducted 
using Stata version 11.0. 
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Results 
Descriptive Data Analysis 
Compared to the control group participants, cases had lower serum levels of estrone and 
free estradiol and higher levels of SHBG (Table 1). No other differences in baseline 
characteristics between cases and controls were found, with near identical medians found 
for BMI, waist circumference, and circulating levels of insulin. Estrone and estradiol had a 
moderate positive correlation with waist circumference and insulin (Supplementary Table 1, 
available online), whereas SHBG was inversely correlated with waist circumference and 
insulin.   
 
Sex Hormone Levels and Risk of Colorectal Cancer 
In the multivariable models, estrone (OR comparing quartile 4 and 1 [q4-q1]=0.50, 95%CI: 
0.33-0.75; P-trend=0.002), free estradiol (OR [q4-q1]=0.43, 95%CI: 0.28-0.67; P-trend=<0.001) 
and total estradiol (OR[q4-q1]=0.64, 95%CI: 0.43-0.97; P-trend=0.12) were inversely 
associated with colorectal cancer (Table 2). These associations were unaffected after 
adjusting simultaneously for serum levels of insulin, CRP, and free IGF-I (estrone, OR[q4-
q1]=0.44, 95%CI: 0.28-0.68, P-trend=0.001; free estradiol, OR[q4-q1]=0.43, 95%CI: 0.27-0.69, P-
trend=<0.0001; and total estradiol, OR[q4-q1]=0.58, 95%CI: 0.38-0.90, P-trend=0.08; Table 3). 
In the restricted cubic spline models, no statistically significant deviations from linearity for 
the relationships between estrone (P-non-linear=0.13), free estradiol (P-non-linear=0.89), 
and total estradiol (P-non-linear=0.87) and colorectal cancer were observed (Figure 1). 
Divergent associations were observed when analyzed by sub-site, with strong inverse 
associations observed for colon cancer, and statistically non-significant positive associations 
observed for rectal cancer; however, the differences between sites were statistically non-
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significant (Table 4; estrone P-heterogeneity=0.15; total estradiol P-heterogeneity=0.13; free 
estradiol P-heterogeneity=0.09). 
 
Levels of SHBG were positively associated with colorectal cancer risk in the multivariable 
model with elevations in risk evident from the second quartile upwards (OR[q2-q1] = 1.69, 
95%CI: 1.16-2.45; OR[q3-q1] = 1.71, 95%CI: 1.16-2.51) and (OR[q4-q1]=2.30, 95%CI: 1.51-3.51) 
(P-trend=<0.0001) (Table 2). Additional adjustments for estrone and estradiol, as well as 
insulin, CRP and free IGF-I, strengthened the positive association between SHBG and 
colorectal cancer (OR[q4-q1]=2.50, 95%CI: 1.59-3.92; P-trend=<0.0001) (Table 3). In the 
restricted cubic spline model, no statistical significant deviation from linearity for the 
relationship between SHBG (P-non-linear=0.08) and colorectal cancer was observed (Figure 
1). The positive association of SHBG with colorectal cancer was consistent for both colon 
and rectal cancer cases separately (Table 4; P-heterogeneity=0.68). We observed no 
association between progesterone level and colorectal cancer in the multivariable model 
(OR[q4-q1]=0.97, 95%CI: 0.66-1.40; P-trend=0.93) (Table 2), and this relationship was 
consistent when colon and rectal cancer was analyzed separately (P-heterogeneity=0.25) 
(further data not shown). Levels of insulin (OR[q4-q1]= 0.76, 95%CI: 0.50-1.14), CRP (OR[q4-
q1]= 0.89, 95%CI: 0.60-1.34) and free IGF-I (OR[q4-q1]= 0.70, 95%CI: 0.48-1.03) were not 
statistically significantly associated with colorectal cancer incidence (Table 2). Waist 
circumference was non-significantly positively associated with colorectal cancer in the 
multivariable model (OR[q4-q1]=1.37, 95%CI: 0.93-2.01; P-trend=0.32) (Table 2); however, this 
association strengthened and became statistically significant after adjusting for insulin, CRP, 
free IGF-I, estradiol, estrone, and SHBG (OR[q4-q1]=2.24, 95%CI: 1.37-3.68; P-trend=0.006) 
(Table 3). Divergent waist circumference associations were observed when analyzed by 
sub-site, with stronger positive associations observed for colon cancer than rectal cancer; 
however, this difference was statistically non-significant (P-heterogeneity=0.21) (further data 
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not shown). Similar strength non-statistically significant positive associations were observed 
for BMI and colorectal, colon, and rectal cancers (data not shown). 
 
None of the associations of the sex hormones with colorectal cancer differed when stratified 
by waist circumference, BMI, or prior HT use and we detected no significant heterogeneity 
between the sex hormones and other serologic factors (Supplementary Table 2). In 
sensitivity analyses, when women with total estradiol levels >30 pg/mL (n=38) and current 
HT users (who had undergone washout period) (n=20) were excluded from the analyses, the 
results were essentially unaltered. Similar relationships were also observed when 
participants who were part of the intervention groups of the DM and CaD study arms were 
excluded; the case-control match was broken and all models were re-analyzed; the cases 
diagnosed within the first three years of follow-up were excluded; the analyses were 
stratified by follow-up time (<5 years and ≥5 years); and when the analyses were limited to 
non-NSAID users only (data not shown).  
 
Discussion 
In this prospective study of postmenopausal women enrolled in the Women’s Health 
Initiative, endogenous estradiol and estrone levels were inversely, and SHBG levels 
positively, associated with colorectal cancer risk, even after control for a number of relevant 
established colorectal cancer risk factors. Each of these associations showed a statistically 
significant biologic gradient. These collective data suggest that endogenous estrogens may 
be biologically related to one or more molecular pathways that are protective against 
colorectal cancer development. 
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To our knowledge, this study is the first to report a statistically significant inverse relationship 
between circulating endogenous estrogen levels and colorectal cancer risk. It is noteworthy 
therefore that several sources of experimental data also suggest that estrogen may have 
protective biologic effects on colorectal cancer development. In vitro studies have shown that 
expression of the β estrogen receptor (ERβ) results in the inhibition of proliferation and G1 
phase cell-cycle arrest in colon cancer cells (20), and in xenograft mouse studies ERβ 
expression has been shown to inhibit cMyc expression and tumor growth (20). Further, 
expression of ERβ is low in human colorectal cancer cells (21) and is inversely associated 
with stage of colon cancer (22), suggesting a possible role in disease progression. 
Consistent with this, it has been reported that there is high CpG island methylation of the 
estrogen receptor gene within colorectal tumors (23).  
 
The current study also found a robust positive association between circulating SHBG levels 
and colorectal cancer risk that was independent of estrogen. SHBG is a hepatically-
synthesized glycoprotein that binds circulating estradiol and testosterone and is therefore an 
important regulator of their bioactivity. In the current analysis, the associations of estrone 
and estradiol with colorectal cancer were unaffected by control for SHBG and similarly, the 
SHBG-colorectal cancer relation was not modified by adjustment for estrone or estradiol. 
This may suggest a novel pathway for SHBG in elevating colorectal cancer risk that is 
independent of estrogen and other related factors, such as hyperinsulinemia. Adjustment for 
circulating testosterone (which was unmeasured in our study) would need to be made to fully 
confirm this hypothesis. To date, the SHBG receptor has yet to be cloned, meaning that 
biological roles beyond sex hormone regulation and transportation are poorly understood. 
Further research on the potential role of SHBG activity in colorectal tumorigenesis is 
warranted. 
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The findings of the current investigation are inconsistent with three prior prospective studies 
that assessed the relationships between endogenous estrogen levels and colorectal cancer, 
including two studies with null results and one which found a positive estrogen-colorectal 
cancer relationship. The latter study was a case-cohort investigation in the WHI-OS that 
included 273 women with colorectal cancer who were not using HT at baseline and observed 
a hazard ratio (HR) of 1.53 (95% CI: 1.05-2.22) for the highest tertile of estradiol after control 
for insulin, free-IGF-I, and waist circumference, as well as other colorectal cancer risk factors 
(11). Two other prospective studies reported no association between circulating sex 
hormones and colorectal cancer. A case-control study nested in the NYUWHS found no 
relation of circulating levels of estradiol, estrone and SHBG with colorectal cancer risk (12). 
A joint NHS and WHS nested case-control analysis with 270 cases also reported no 
statistically significant relationships for colorectal cancer risk with these same serologic 
measures (13). However, the NHS/WHS study did observe an inverse association for 
colorectal cancer risk with the ratio of total estradiol to testosterone, a finding that the 
authors hypothesized reflected greater aromatase expression and, as a consequence, 
higher estradiol synthesis (13).  
 
Reasons for the difference in the results from the current analysis compared with the prior 
investigations are not entirely clear. Possible explanations for the divergent results include 
that our analysis is considerably larger than the previous studies, we used the current gold 
standard sex hormone assays, performed individual matching for important risk factors, and 
had the most thorough covariate information available of any study to date investigating 
these relationships. Of note, circulating estradiol levels were relatively similar between our 
analysis and the previous studies (11-13). However, estrone levels were substantially higher 
in the current study (quartile 1 to quartile 4 <32.5 to ≥57.28 pg/mL) compared to the joint 
NHS/WHS (quartile 1 to quartile 4 range: 6-16 to ≥32 pg/mL; quartile 1 to quartile 4 range: 5-
19 to ≥37 pg/mL) (13) and NYUWHS (quartile 1 to quartile 4 range: ≤13 to ≥26 pg/mL) 
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analyses (12). Further, our analyses of non-linear effects showed that statistically significant 
lower colorectal cancer risks were only observed at estrone levels over ~60 pg/mL when 
compared against the reference level (32.4 pg/mL). Thus, it is possible that estrone, and not 
estradiol, is driving the inverse relationships we observed, and the null results found in the 
NHS/WHS and NYUWHS studies are the consequence of lower measured estrone levels. 
Unfortunately, due to the high correlation between estradiol and estrone (r = 0.82) we could 
not disentangle these relationships and further studies are warranted to investigate which 
estrogenic components are most relevant for colorectal cancer in post-menopausal women. 
 
Interestingly, the results of the current study may also enhance understanding of the 
established positive association between adiposity and colorectal cancer (24;25). It has been 
consistently shown that the positive relationships between obesity and colorectal cancer are 
weaker among women than men (24). One proposed explanation for this sex difference is 
that higher circulating estrogens in women may mitigate the potential tumorigenic effects of 
excess adiposity on the colorectum (26). In our analysis, the waist circumference and 
colorectal cancer relationship strengthened and became statistically significant after the 
multivariable models were additionally adjusted for estrone, estradiol, and SHBG. This 
suggests that the estrogen-colorectal cancer association may indeed mask the adiposity-
colorectal cancer relation in women and future studies that investigate this hypothesis should 
incorporate estrogen measurements to limit the effects of this confounding bias. 
 
A strength of our analysis is that virtually all women were non-HT users (98.8% of cases and 
98% of controls) at baseline, and the remaining current users underwent a washout period. 
Analysis with this latter small group of women excluded produced essentially unchanged 
findings. The vast majority of women were never users of HT (70.8% of cases and 75.1% of 
controls). A limitation of our analysis is that sex hormone levels were measured only once at 
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baseline and it is possible that these measurements may not reflect exposure levels across 
time. However, a previous analysis of postmenopausal women reported that the within-
person correlation coefficients for free estradiol, estrone and SHBG over a 2-3 year period 
were 0.73, 0.74 and 0.92 respectively (27), indicating that single measurements provide 
good estimates of longer term exposures. A further possible explanation for our results was 
that pre-clinical disease at baseline may have introduced bias (reverse causality) into our 
analyses. However, all of the 401 colorectal cancer cases were diagnosed after more than 1 
year of follow-up. Furthermore, our results remained essentially unaltered when cases 
diagnosed within the first 3 years of follow-up were excluded, and when the analyses were 
stratified by follow-up time (<5 years and ≥5 years). Finally, our study lacked data on 
testosterone and other hormones related to the estrogen and SHBG pathway. Future studies 
should incorporate testosterone and other androgen measurements into analyses to further 
inform on the role of the sex hormone axis in colorectal tumorigenesis 
 
In conclusion, in this prospective analysis of postmenopausal women, endogenous levels of 
estrogens were inversely, and SHBG levels positively, associated with colorectal cancer 
and, in the case of estrogens, the association was confined to colon cancer. These 
associations were independent of other colorectal cancer risk factors and are consistent with 
mechanistic data and observational studies of exogenous hormone use and colorectal 
cancer risk. While further studies of the relationships between endogenous sex hormone 
levels, SHBG and colorectal cancer are warranted; these findings suggest that endogenous 
estrogens may confer a protective effect on colorectal cancer development in post-
menopausal women. 
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Figure Legend 
 
Figure 1. Association between circulating A) estradiol, B) estrone, C) free estradiol, and 
D) SHBG with colorectal cancer allowing for non-linear effects (restricted cubic spline).  
Solid lines indicate the odds ratio and shaded grey areas indicate the 95% confidence 
intervals.  Multivariable models only - adjusted for waist circumference, alcohol 
consumption, family history of colorectal cancer, physical activity, smoking status, and 
NSAID use. Estradiol and estrone models additionally adjusted for insulin, IGF-I, CRP, 
and SHBG. Free estradiol model additionally adjusted for insulin, IGF-I, and CRP. SHBG 
model additionally adjusted for insulin, IGF-I, CRP, estradiol, and estrone. The 
references for these restricted cubic spline plots ( with five knots placed at the 10th, 
25th, 50th, 75th, and 95th percentiles) were estradiol 7 pg/mL, estrone 32.4 pg/mL, free 
estradiol 0.17 pg/mL, and SHBG 22 nmol/L.   
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Table 1.  Selected baseline characteristics of cases and controls 
Variable Cases Controls P-value * 
    (n = 401) (n = 802)   
Age (years) ‡ 66.0 (61.0 - 71.0) 66.0 (61.0 - 71.0) 0.99 
Ethnicity †         0.99 
  White 327 (81.6) 654 (81.6)   
  Black 46 (11.5) 92 (11.5)   
  Hispanic 10 (2.5) 20 (2.5)   
  Other/unknown 18 (4.5) 36 (4.5)   
Weight (kg) ‡ 74.6 (65.4 - 85.7) 74.0 (64.4 - 87.5) 0.95 
Body mass index (kg/m
2
) ‡ 28.5 (25.1 - 32.5) 28.4 (25.0 - 33.0) 0.83 
Waist circumference (cm) ‡ 89.0 (81.0 - 100.0) 89.0 (79.0 - 99.0) 0.46 
Waist-to-hip ratio ‡ 0.82 (0.8 - 0.9) 0.82 (0.8 - 0.9) 0.46 
Past HT usage status †         0.11 
  Never 284 (70.8) 602 (75.1)   
  Former 111 (27.7) 184 (22.9)   
  Current 5 (1.3) 16 (2.0)   
  Missing 1 (0.3) 0 (0.0)   
NSAID use †         0.20 
  No 277 (69.1) 524 (65.3)   
  Yes 124 (30.9) 278 (34.7)   
Family history of colorectal cancer †       0.59 
  No 299 (74.6) 616 (76.8)   
  Yes 68 (17.0) 118 (14.7)   
  Missing 34 (8.5) 68 (8.5)   
Smoking status †         0.12 
  Never 185 (46.1) 420 (52.4)   
  Former 181 (45.1) 304 (37.9)   
  Current 29 (7.2) 63 (7.9)   
  Missing 6 (1.5) 15 (1.9)   
Alcohol (servings per week) †         0.22 
  Non-consumers 175 (43.7) 364 (45.4)   
  0.1-<3.0 125 (31.2) 265 (33.0)   
  ≥3.0 97 (24.2) 171 (21.3)   
  Missing 4 (1.0) 2 (0.3)   
Physical activity (MET-hours per week) †       0.71 
  <3.75 133 (33.2) 268 (33.4)   
  3.75-<9.83 102 (25.4) 176 (22.0)   
  9.83-<18.75 65 (16.2) 142 (17.7)   
  ≥18.75 67 (16.7) 147 (18.3)   
  Missing 34 (8.5) 69 (8.6)   
Serological variables ‡           
  Estradiol (pg/mL) 9.4 (6.8 - 12.8) 9.5 (7.1 - 13.8) 0.22 
  Estrone (pg/mL) 40.7 (31.2 - 53.5) 43.0 (32.4 - 57.3) 0.02 
  Progesterone (pg/mL) 47.4 (36.1 - 62.0) 46.2 (34.9 - 62.9) 0.68 
  Free estradiol (pg/mL) 0.23 (0.2 - 0.3) 0.25 (0.2 - 0.4) 0.04 
  SHBG (nmol/L) 44.3 (33.5 - 64.4) 42.4 (29.6 - 60.3) 0.02 
  Insulin (µIU/mL) 5.6 (2.8 - 9.6) 5.7 (2.9 - 10.1) 0.50 
  C-reactive protein (mg/L) 2.8 (1.4 - 6.0) 3.0 (1.2 - 6.1) 0.99 
  Free IGF-I (ng/mL) 0.8 (0.4 - 1.1) 0.8 (0.5 - 1.1) 0.43 
‡ Values are medians (IQR). 
† Values are n (%). 
* Calculated using Wilcoxon two-sample tests for continuous variables and χ2 tests for categorical variables. All statistical tests 
were two-sided.
22 
 
Table 2.  Association of circulating levels of sex hormones, SHBG, insulin, CRP, free IGF-I 
and waist circumference with colorectal cancer in WHI-CT participants 
Variables 
  
Quartile 1 
  
Quartile 2 
  
Quartile 3 
  
Quartile 4 
  
P-trend† 
  
Estradiol           
  Quartile cutpoints, pg/mL <7.09 7.09-<9.46 9.46-13.90 ≥13.90   
  N (Cases/Controls) 110/201 91/200 121/201 79/200   
  Unadjusted Model OR (95% CI)  1.00 0.81 (0.57-1.15) 1.07 (0.77-1.49) 0.70 (0.48-1.01) 0.23 
  Multivariable-adjusted OR‡ (95% CI) 1.00 0.79 (0.55-1.13) 0.99 (0.69-1.40) 0.64 (0.43-0.97) 0.12 
Estrone           
  Quartile cutpoints, pg/mL <32.50 32.50-<43.03 43.03-<57.28 ≥57.28   
  N (Cases/Controls) 114/201 115/200 103/201 69/200   
  Unadjusted Model OR (95% CI)  1.00 0.98 (0.71-1.37) 0.88 (0.63-1.23) 0.58 (0.39-0.84) 0.005 
  Multivariable-adjusted OR‡ (95% CI) 1.00 0.94 (0.66-1.32) 0.87 (0.61-1.23) 0.50 (0.33-0.75) 0.002 
Progesterone           
  Quartile cutpoints, pg/mL <34.94 34.94-<46.24 46.24-<63.21 ≥63.21   
  N (Cases/Controls) 97/201 97/200 115/201 92/200   
  Unadjusted Model OR (95% CI)  1.00 1.01 (0.71-1.42) 1.20 (0.85-1.71) 0.95 (0.66-1.37) 0.94 
  Multivariable-adjusted OR‡ (95% CI) 1.00 1.02 (0.72-1.46) 1.19 (0.83-1.72) 0.97 (0.66-1.40) 0.93 
SHBG           
  Quartile cutpoints, nmol/L <29.70 29.70-<42.50 42.50-<60.40 ≥60.40   
  N (Cases/Controls) 70/201 110/201 104/201 117/199   
  Unadjusted Model OR (95% CI)  1.00 1.59 (1.11-2.29) 1.52 (1.06-2.18) 1.75 (1.21-2.52) 0.009 
  Multivariable-adjusted OR‡ (95% CI) 1.00 1.69 (1.16-2.45) 1.71 (1.16-2.51) 2.30 (1.51-3.51) <0.0001 
Free Estradiol           
  Quartile cutpoints, pg/mL <0.18 0.18-<0.26 0.26-<0.38 ≥0.38   
  N (Cases/Controls) 123/205 114/215 93/188 71/194   
  Unadjusted Model OR (95% CI)  1.00 0.85 (0.62-1.18) 0.80 (0.57-1.13) 0.58 (0.40-0.84) 0.005 
  Multivariable-adjusted OR‡ (95% CI) 1.00 0.74 (0.52-1.05) 0.66 (0.45-0.96) 0.43 (0.28-0.67) <0.001 
Insulin           
  Quartile cutpoints, uIU/mL <2.88 2.88-<5.73 5.73-<10.2 ≥10.2   
  N (Cases/Controls) 105/201 98/199 104/202 94/197   
  Unadjusted Model OR (95% CI)  1.00 0.94 (0.66-1.33) 0.98 (0.70-1.38) 0.91 (0.65-1.28) 0.66 
  Multivariable-adjusted OR‡ (95% CI) 1.00 0.89 (0.61-1.29) 0.88 (0.60-1.29) 0.76 (0.50-1.14) 0.21 
CRP           
  Quartile cutpoints, mg/L <1.24 1.24-<2.96 2.96-<6.12 ≥6.12   
  N (Cases/Controls) 92/202 114/199 105/203 90/198   
  Unadjusted Model OR (95% CI)  1.00 1.25 (0.89-1.75) 1.14 (0.79-1.63) 1.00 (0.69-1.44) 0.83 
  Multivariable-adjusted OR‡ (95% CI) 1.00 1.18 (0.83-1.67) 1.06 (0.72-1.56) 0.89 (0.60-1.34) 0.47 
Free IGF-I           
  Quartile cutpoints, ng/mL <0.47 0.47-<0.79 0.79-<1.15 ≥1.15   
  N (Cases/Controls) 117/205 89/198 108/199 87/200   
  Unadjusted Model OR (95% CI)  1.00 0.78 (0.55-1.10) 0.94 (0.67-1.31) 0.74 (0.51-1.06) 0.21 
  Multivariable-adjusted OR‡ (95% CI) 1.00 0.78 (0.55-1.12) 0.93 (0.67-1.31) 0.70 (0.48-1.03) 0.15 
Waist circumference           
  Quartile cutpoints, cm <79.2 79.2-<89.4 89.4-<99.1 ≥99.1   
  N (Cases/Controls) 95/226 108/184 95/194 101/196   
  Unadjusted Model OR (95% CI)  1.00 1.58 (1.12-2.23) 1.28 (0.89-1.84) 1.40 (0.97-2.03) 0.24 
  Multivariable-adjusted OR‡ (95% CI) 1.00 1.54 (1.09-2.19) 1.23 (0.85-1.78) 1.37 (0.93-2.01) 0.32 
† Statistical tests for trend (two-sided) were calculated using ordinal quartile variables (1–4) entered into the model as a single 
continuous variable. 
‡ Multivariable model adjusted for waist circumference, alcohol consumption, family history of colorectal cancer, physical 
activity, smoking status, and NSAID use. 
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Table 3.  Association of circulating levels of sex hormones, SHBG and waist circumference 
with colorectal cancer after additional adjustment for insulin, free IGF-I and CRP 
 Variables 
  
Quartile 1 
  
Quartile 2 
  
Quartile 3 
  
Quartile 4 
  
P-trend† 
  
Estradiol           
Quartile cutpoints, pg/mL <7.09 7.09-<9.46 9.46-13.90 ≥13.90   
N (Cases/Controls) 110/201 91/200 121/201 79/200   
Multivariable-adjusted OR‡ (95% CI) 1.00 0.79 (0.55-1.13) 0.99 (0.69-1.40) 0.64 (0.43-0.97) 0.12 
Multivariable-adjusted + insulin, IGF-I , 
CRP and SHBG OR‡ (95% CI) 1.00 0.83 (0.57-1.20) 1.03 (0.72-1.48) 0.58 (0.38-0.90) 0.08 
            
Estrone           
Quartile cutpoints, pg/mL <32.50 32.50-<43.03 43.03-<57.28 ≥57.28   
N (Cases/Controls) 114/201 115/200 103/201 69/200   
Multivariable-adjusted OR‡ (95% CI) 1.00 0.94 (0.66-1.32) 0.87 (0.61-1.23) 0.50 (0.33-0.75) 0.002 
Multivariable-adjusted + insulin, IGF-I , 
CRP and SHBG OR‡ (95% CI) 1.00 0.95 (0.67-1.34) 0.89 (0.62-1.27) 0.44 (0.28-0.68) 0.001 
            
SHBG           
Quartile cutpoints, nmol/L <29.70 29.70-<42.50 42.50-<60.40 ≥60.40   
N (Cases/Controls) 70/201 110/201 104/201 117/199   
Multivariable-adjusted OR‡ (95% CI) 1.00 1.69 (1.16-2.45) 1.71 (1.16-2.51) 2.30 (1.51-3.51) <0.0001 
Multivariable-adjusted + insulin, IGF-I, 
CRP, estradiol and estrone OR‡ (95% CI) 1.00 1.71 (1.17-2.49) 1.69 (1.13-2.52) 2.50 (1.59-3.92) <0.0001 
            
Free Estradiol           
Quartile cutpoints, pg/mL <0.18 0.18-<0.26 0.26-<0.38 ≥0.38   
N (Cases/Controls) 123/205 114/215 93/188 71/194   
Multivariable-adjusted OR‡ (95% CI) 1.00 0.74 (0.52-1.05) 0.66 (0.45-0.96) 0.43 (0.28-0.67) <0.0001 
Multivariable-adjusted + insulin, IGF-I and 
CRP OR‡ (95% CI) 1.00 0.75 (0.53-1.08) 0.67 (0.45-0.99) 0.43 (0.27-0.69) <0.0001 
            
Waist circumference           
Quartile cutpoints, cm <79.2 79.2-<89.4 89.4-<99.1 ≥99.1   
N (Cases/Controls) 95/226 108/184 95/194 101/196   
Multivariable-adjusted OR‡ (95% CI) 1.00 1.54 (1.09-2.19) 1.23 (0.85-1.78) 1.37 (0.93-2.01) 0.32 
Multivariable-adjusted + insulin, IGF-I, 
CRP, estradiol, estrone, and SHBG OR‡ 
(95% CI) 1.00 1.87 (1.28-2.73) 1.77 (1.14-2.76) 2.24 (1.37-3.68) 0.006 
† Statistical tests for trend (two-sided) were calculated using ordinal quartile variables (1–4) entered into the model as a single 
continuous variable. 
‡ Multivariable model adjusted for waist circumference, alcohol consumption, family history of colorectal cancer, physical 
activity, smoking status, and NSAID use. 
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Table 4.  Association of circulating levels of sex hormones, and SHBG with colon and rectal cancers after 
additional adjustment for insulin, free IGF-I and CRP 
 Variables 
  
  
Quantiles*  
  
  
P-trend†  
P-heterogeneity 
colon vs. rectal 
Estradiol           
0.13 
  Colon cancer (n=303) Quartile 1 Quartile 2 Quartile 3 Quartile 4    
    
Multivariable-adjusted + insulin, 
IGF-I , CRP and SHBG OR‡ (95% 
CI) 
1.00 0.71 (0.46-1.09) 0.90 (0.59-1.37) 0.39 (0.23-0.64) 0.003 
 
  Rectal cancer (n=93) Tertile 1 Tertile 2 Tertile 3      
    
Multivariable-adjusted + insulin, 
IGF-I , CRP and SHBG OR‡ (95% 
CI) 
1.00 1.11 (0.54-2.27) 1.44 (0.63-3.28)   0.39 
 
                 
Estrone            
  Colon cancer (n=303) Quartile 1 Quartile 2 Quartile 3 Quartile 4   0.15 
    
Multivariable-adjusted + insulin, 
IGF-I , CRP and SHBG OR‡ (95% 
CI) 
1.00 0.79 (0.52-1.19) 0.70 (0.46-1.07) 0.34 (0.21-0.57) <0.001 
 
  Rectal cancer (n=93) Tertile 1 Tertile 2 Tertile 3      
    
Multivariable-adjusted + insulin, 
IGF-I , CRP and SHBG OR‡ (95% 
CI) 
1.00 1.78 (0.85-3.74) 1.13 (0.49-2.62)   0.79 
 
                 
SHBG            
  Colon cancer (n=303) Quartile 1 Quartile 2 Quartile 3 Quartile 4   0.68 
    
Multivariable-adjusted + insulin, 
IGF-I, CRP, estradiol and estrone 
OR‡ (95% CI) 
1.00 1.72 (1.08-2.72) 1.66 (1.02-2.71) 2.35 (1.36-4.07) 0.006  
  Rectal cancer (n=93) Tertile 1 Tertile 2 Tertile 3      
    
Multivariable-adjusted + insulin, 
IGF-I, CRP, estradiol and estrone 
OR‡ (95% CI) 
1.00 2.03 (0.94-4.37) 3.02 (1.31-6.98)   0.01  
                 
Free Estradiol           0.09 
  Colon cancer (n=303) Quartile 1 Quartile 2 Quartile 3 Quartile 4    
    
Multivariable-adjusted + insulin, 
IGF-I and CRP OR‡ (95% CI) 1.00 0.69 (0.46-1.05) 0.65 (0.41-1.03) 0.28 (0.16-0.49) <0.001  
  Rectal cancer (n=93) Tertile 1 Tertile 2 Tertile 3      
    
Multivariable-adjusted + insulin, 
IGF-I and CRP OR‡ (95% CI) 1.00 0.82 (0.41-1.66) 1.40 (0.62-3.18)   0.43  
*Quartile cutpoints: estradiol (<7.09, 7.09-<9.46, 9.46-<13.90, ≥13.90 pg/mL), estrone (<32.50, 32.50-<43.03, 43.03-<57.28, ≥57.28 pg/mL), 
SHBG (<29.70, 29.70-<42.50, 42.50-<60.40, ≥60.40 nmol/L), and free estradiol (<0.18, 0.18-<0.26, 0.26-<0.38, ≥0.38 pg/mL). Tertile cutpoints: 
estradiol (<7.85, 7.85-<11.97, ≥11.97 pg/mL), estrone (<35.73, 35.73-<52.06, ≥52.06 pg/mL), SHBG (<34.60, 34.60-<52.90, ≥52.90 nmol/L), and 
free estradiol (<0.20, 0.20-<0.32, ≥0.32 pg/mL).  
† Statistical tests for trend (two-sided) were calculated using ordinal quartile (1–4) or tertile (1-3) variable entered into the model as a single 
continuous variable. 
‡Multivariable model adjusted for waist circumference, alcohol consumption, family history of colorectal cancer, physical activity, smoking status, 
and NSAID use. 
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